Samsung Biologics Co Ltd (207940) — Capital Reinvestment Ratio
Latest as of September 2025:
0.18x
Samsung Biologics Co Ltd (207940) has a Capital Reinvestment Ratio of 0.18x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩619.30 Billion) in capital expenditures (₩113.81 Billion). See 207940 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.18x
Capex / Operating Cash Flow
Operating Cash Flow
₩619.30 Billion
KRW
Capital Expenditures
₩113.81 Billion
KRW
Data as of
Sep 2025
Most recent filing
Samsung Biologics Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Samsung Biologics Co Ltd's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Samsung Biologics Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Samsung Biologics Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see 207940 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.83x | ₩1.66 Trillion | ₩1.38 Trillion | ▲ +25.2% |
| 2023 | 0.66x | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -33.9% |
| 2022 | 1.00x | ₩953.05 Billion | ₩956.84 Billion | ▲ +12.3% |
| 2021 | 0.89x | ₩454.60 Billion | ₩406.25 Billion | ▲ +29.3% |
| 2020 | 0.69x | ₩202.09 Billion | ₩139.66 Billion | ▼ -96.4% |
| 2019 | 18.99x | ₩10.15 Billion | ₩192.84 Billion | ▲ +475.8% |
| 2017 | 3.30x | ₩149.82 Billion | ₩494.12 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow